These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 20332435)
1. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Patel BB; Gupta D; Elliott AA; Sengupta V; Yu Y; Majumdar AP Anticancer Res; 2010 Feb; 30(2):319-25. PubMed ID: 20332435 [TBL] [Abstract][Full Text] [Related]
2. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Patel BB; Sengupta R; Qazi S; Vachhani H; Yu Y; Rishi AK; Majumdar AP Int J Cancer; 2008 Jan; 122(2):267-73. PubMed ID: 17918158 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells. Reddy S; Rishi AK; Xu H; Levi E; Sarkar FH; Majumdar AP Nutr Cancer; 2006; 55(2):185-94. PubMed ID: 17044774 [TBL] [Abstract][Full Text] [Related]
4. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Nautiyal J; Banerjee S; Kanwar SS; Yu Y; Patel BB; Sarkar FH; Majumdar AP Int J Cancer; 2011 Feb; 128(4):951-61. PubMed ID: 20473900 [TBL] [Abstract][Full Text] [Related]
5. Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Yu Y; Kanwar SS; Patel BB; Nautiyal J; Sarkar FH; Majumdar AP Transl Oncol; 2009 Dec; 2(4):321-8. PubMed ID: 19956394 [TBL] [Abstract][Full Text] [Related]
6. Gercumin synergizes the action of 5-fluorouracil and oxaliplatin against chemoresistant human cancer colon cells. Genovese S; Epifano F; Preziuso F; Slater J; Nangia-Makker P; Majumdar APN; Fiorito S Biochem Biophys Res Commun; 2020 Jan; 522(1):95-99. PubMed ID: 31740005 [TBL] [Abstract][Full Text] [Related]
7. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Kanwar SS; Yu Y; Nautiyal J; Patel BB; Padhye S; Sarkar FH; Majumdar AP Pharm Res; 2011 Apr; 28(4):827-38. PubMed ID: 21161336 [TBL] [Abstract][Full Text] [Related]
8. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. Vanamala J; Reddivari L; Radhakrishnan S; Tarver C BMC Cancer; 2010 May; 10():238. PubMed ID: 20504360 [TBL] [Abstract][Full Text] [Related]
9. Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. Oh PS; Patel VB; Sanders MA; Kanwar SS; Yu Y; Nautiyal J; Patel BB; Majumdar AP Am J Physiol Gastrointest Liver Physiol; 2011 Aug; 301(2):G347-55. PubMed ID: 21596996 [TBL] [Abstract][Full Text] [Related]
10. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. Codony-Servat J; Cuatrecasas M; Asensio E; Montironi C; Martínez-Cardús A; Marín-Aguilera M; Horndler C; Martínez-Balibrea E; Rubini M; Jares P; Reig O; Victoria I; Gaba L; Martín-Richard M; Alonso V; Escudero P; Fernández-Martos C; Feliu J; Méndez JC; Méndez M; Gallego J; Salud A; Rojo F; Castells A; Prat A; Rosell R; García-Albéniz X; Camps J; Maurel J Br J Cancer; 2017 Dec; 117(12):1777-1786. PubMed ID: 29123263 [TBL] [Abstract][Full Text] [Related]
11. Curcumin synergizes the growth inhibitory properties of Indian toad (Bufo melanostictus Schneider) skin-derived factor (BM-ANF1) in HCT-116 colon cancer cells. Giri B; Gomes A; Sengupta R; Banerjee S; Nautiyal J; Sarkar FH; Majumdar AP Anticancer Res; 2009 Jan; 29(1):395-401. PubMed ID: 19331178 [TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation. Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346 [TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799 [TBL] [Abstract][Full Text] [Related]
14. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Kaulfuss S; Burfeind P; Gaedcke J; Scharf JG Mol Cancer Ther; 2009 Apr; 8(4):821-33. PubMed ID: 19372555 [TBL] [Abstract][Full Text] [Related]
15. Curcumin synergizes with resveratrol to inhibit colon cancer. Majumdar AP; Banerjee S; Nautiyal J; Patel BB; Patel V; Du J; Yu Y; Elliott AA; Levi E; Sarkar FH Nutr Cancer; 2009; 61(4):544-53. PubMed ID: 19838927 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. Jones HE; Gee JM; Barrow D; Tonge D; Holloway B; Nicholson RI Br J Cancer; 2006 Jul; 95(2):172-80. PubMed ID: 16819546 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit. Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701 [TBL] [Abstract][Full Text] [Related]
18. The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells. Hosseini SA; Zand H; Cheraghpour M Medicina (Kaunas); 2019 Apr; 55(4):. PubMed ID: 30987250 [No Abstract] [Full Text] [Related]
19. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682 [TBL] [Abstract][Full Text] [Related]
20. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Cascinu S; Berardi R; Salvagni S; Beretta GD; Catalano V; Pucci F; Sobrero A; Tagliaferri P; Labianca R; Scartozzi M; Crocicchio F; Mari E; Ardizzoni A Br J Cancer; 2008 Jan; 98(1):71-6. PubMed ID: 18059397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]